{"id":{"repo_id":"usfca","oai_identifier":"oai:repository.usfca.edu:dnp-1198"},"canonical_url":"https://search.ndltd.org/etd/usfca/oai:repository.usfca.edu:dnp-1198","repository":{"repo_id":"usfca","name":"University of San Francisco","base_url":"https://repository.usfca.edu/do/oai/"},"display":{"title":"Hepatitis C Treatment in High Risk Patients: Implementation of a Successful Community Focused Program","abstract":"Background: The city of San Francisco boasts a high rate of hepatitis C infection (HCV) among IV drug users indicating the need for a hepatitis C treatment program. It is estimated that over two-thirds of people who are actively infected with HCV are IV drug users (EndHepCSF, 2017), and in 2017 the San Francisco Department of Public Health (SFDPH) estimated that there are 22,500 active people who inject drugs (PWID) in SF (SFDPH, 2017). With the presence of a wide population of IV drug users in SF there is an identified need for intervention to treat this high-risk patient population. Methods: After identification of a significant population of HCV infected patients in a community clinic, the latest evidence for HCV treatment was used to develop and pilot a practical HCV treatment program using glecaprevir/pibrentasvir (Mavyret). The pilot was aimed at testing a protocol in primary care, utilizing evidence based strategies. Results: A total of 6 patients were enrolled in the pilot. There was a successful response rate (100% SVR) among the treatment group, supporting the use of single drug treatment with observed therapy in high risk populations. Conclusion: The results of the project demonstrated that a standardized hepatitis C treatment program is highly efficacious and can be delivered in primary care settings to patients who are high risk.","abstract_html":"Background: The city of San Francisco boasts a high rate of hepatitis C infection (HCV) among IV drug users indicating the need for a hepatitis C treatment program. It is estimated that over two-thirds of people who are actively infected with HCV are IV drug users (EndHepCSF, 2017), and in 2017 the San Francisco Department of Public Health (SFDPH) estimated that there are 22,500 active people who inject drugs (PWID) in SF (SFDPH, 2017). With the presence of a wide population of IV drug users in SF there is an identified need for intervention to treat this high-risk patient population. Methods: After identification of a significant population of HCV infected patients in a community clinic, the latest evidence for HCV treatment was used to develop and pilot a practical HCV treatment program using glecaprevir/pibrentasvir (Mavyret). The pilot was aimed at testing a protocol in primary care, utilizing evidence based strategies. Results: A total of 6 patients were enrolled in the pilot. There was a successful response rate (100% SVR) among the treatment group, supporting the use of single drug treatment with observed therapy in high risk populations. Conclusion: The results of the project demonstrated that a standardized hepatitis C treatment program is highly efficacious and can be delivered in primary care settings to patients who are high risk.","abstract_has_math":false,"creators":["Pedlar, Annie","Sandhu, Jodie, DNP, FNP-C"],"institution":null,"degree_name":"Doctor of Nursing Practice (DNP)","degree_level":"Project","degree_discipline":"Nursing","degree_department":null,"school":null,"contributors":["Prabjot (Jodie) Sandhu","Wanda Borges"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T08:36:36Z","subjects":["Keywords: HCV","PWID","barriers","adherence","treatment","recommendations","education","awareness","resources","increase rates.","Nursing"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://repository.usfca.edu/dnp/172","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://repository.usfca.edu/dnp/172","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://repository.usfca.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Arepository.usfca.edu%3Adnp-1198","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Prabjot (Jodie) Sandhu","Wanda Borges"]},{"key":"dc:creator","label":"Author","values":["Pedlar, Annie","Sandhu, Jodie, DNP, FNP-C"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2019-10-23T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2019-05-10T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Nursing"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Project"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Nursing Practice (DNP)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Keywords: HCV","PWID","barriers","adherence","treatment","recommendations","education","awareness","resources","increase rates.","Nursing"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://repository.usfca.edu/dnp/172"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Background: The city of San Francisco boasts a high rate of hepatitis C infection (HCV) among IV drug users indicating the need for a hepatitis C treatment program. It is estimated that over two-thirds of people who are actively infected with HCV are IV drug users (EndHepCSF, 2017), and in 2017 the San Francisco Department of Public Health (SFDPH) estimated that there are 22,500 active people who inject drugs (PWID) in SF (SFDPH, 2017). With the presence of a wide population of IV drug users in SF there is an identified need for intervention to treat this high-risk patient population. Methods: After identification of a significant population of HCV infected patients in a community clinic, the latest evidence for HCV treatment was used to develop and pilot a practical HCV treatment program using glecaprevir/pibrentasvir (Mavyret). The pilot was aimed at testing a protocol in primary care, utilizing evidence based strategies. Results: A total of 6 patients were enrolled in the pilot. There was a successful response rate (100% SVR) among the treatment group, supporting the use of single drug treatment with observed therapy in high risk populations. Conclusion: The results of the project demonstrated that a standardized hepatitis C treatment program is highly efficacious and can be delivered in primary care settings to patients who are high risk."]},{"key":"dc:title","label":"Title","values":["Hepatitis C Treatment in High Risk Patients: Implementation of a Successful Community Focused Program"]}]}],"canonical_facts":{"dc:contributor":["Prabjot (Jodie) Sandhu","Wanda Borges"],"dc:creator":["Pedlar, Annie","Sandhu, Jodie, DNP, FNP-C"],"dc:date.available":["2019-10-23T07:00:00Z"],"dc:date.created":["2019-05-10T07:00:00Z"],"dc:description.abstract":["Background: The city of San Francisco boasts a high rate of hepatitis C infection (HCV) among IV drug users indicating the need for a hepatitis C treatment program. It is estimated that over two-thirds of people who are actively infected with HCV are IV drug users (EndHepCSF, 2017), and in 2017 the San Francisco Department of Public Health (SFDPH) estimated that there are 22,500 active people who inject drugs (PWID) in SF (SFDPH, 2017). With the presence of a wide population of IV drug users in SF there is an identified need for intervention to treat this high-risk patient population. Methods: After identification of a significant population of HCV infected patients in a community clinic, the latest evidence for HCV treatment was used to develop and pilot a practical HCV treatment program using glecaprevir/pibrentasvir (Mavyret). The pilot was aimed at testing a protocol in primary care, utilizing evidence based strategies. Results: A total of 6 patients were enrolled in the pilot. There was a successful response rate (100% SVR) among the treatment group, supporting the use of single drug treatment with observed therapy in high risk populations. Conclusion: The results of the project demonstrated that a standardized hepatitis C treatment program is highly efficacious and can be delivered in primary care settings to patients who are high risk."],"dc:identifier":["https://repository.usfca.edu/dnp/172"],"dc:subject":["Keywords: HCV","PWID","barriers","adherence","treatment","recommendations","education","awareness","resources","increase rates.","Nursing"],"dc:title":["Hepatitis C Treatment in High Risk Patients: Implementation of a Successful Community Focused Program"],"thesis:degree_discipline":["Nursing"],"thesis:degree_level":["Project"],"thesis:degree_name":["Doctor of Nursing Practice (DNP)"]},"updated_at":"2026-11-19T08:36:36Z"}